Number of patients who received at least one prescription for a COX-2 inhibitor or NSAID after hospital discharge Drug Patients % of study cohort Rofecoxib.

Slides:

Advertisements

Similar presentations

Are all COX-2 medicines the same? Pharmacokinetics and metabolism of coxibs t max (h) Bioavailabili ty (oral, %) t 50% (h) Primary metabolism 5 (cytochrome.

Advertisements

Department of Health and Human Services Center for Drug Evaluation and Research Review of Epidemiologic Studies on Cardiovascular Risk with Selected NSAIDs.

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 71 Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen.

NSAIDS in the ischaemic heart disease patient

Treating to New Targets Study TNT Trial Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa.

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

An epidemiologic perspective on etoricoxib David J. Graham, MD, MPH Office of Surveillance and Epidemiology April 12, 2007.

Gastrointestinal Review Highlights of the VIGOR Trial Lawrence Goldkind M.D.

Farrokh Alemi, Ph.D..  Compare effectiveness  Low dose rofecoxib (Vioxx)  High dose rofecoxib (Vioxx)  Celecoxib  Other medication.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting April 12, 2007 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory.

Summary Pattern of Specific COX II Inhibitors Use Physician prescribed appropriate COX II use in high risk was 40.08% and inappropriate COX II use in low.

NDAs /772 Etoricoxib Robert B. Shibuya, M.D. Medical Officer Division of Anesthesia, Analgesia, and Rheumatology Products.

Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.

NSAIDs: Risk of acute MI compared with remote use Largest NSAID database study ever casts doubt on entire coxib controvers [Rheumawire > News; Jun 10,

Small Bowel Toxicity of Nonselective NSAIDs Revealed by Capsule Endoscopy: Results From a Pivotal Clinical Trial Glenn M. Eisen, M.D., M.P.H. Associate.

Hot Topic Presentation Lars Halford, GP ST3 March 2010

East & South East England Specialist Pharmacy Services East of England, London, South Central & South East Coast NSAIDS – Efficacy and Safety Expert speaker.

Date of download: 6/3/2016 From: Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial.

JAMA Internal Medicine May 2015 Volume 175, Number5 R1 조한샘 / Prof. 이창균.

NHS Specialist Pharmacy Service NSAIDS – efficacy and safety Expert speaker Slide set Key content from the NPC NSAIDS QIPP slides is gratefully acknowledged.

Date of download: 9/19/2016 From: Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use: A Nationwide.

Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.

Chapter 71 Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen 1.

Rachel Kim, PharmD Candidate Cone Health Family Medicine

Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen 1.

The American College of Cardiology Presented by Dr. Adnan Kastrati

Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.

Copyright © 2000 American Medical Association. All rights reserved.

Therapeutics Initiative Drug Assessment Working Group

Copyright © 2006 American Medical Association. All rights reserved.

Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes by Gunnar H. Gislason, Jeppe N. Rasmussen, Steen.

Selection of NSAIDs for Osteoarthritis

End point Patients >75 y with renal insufficiency

Adjusted odds ratio 95% CI Diagnostic angiography PCI CABG

51st Annual Scientific Session for the LIFE Investigators

Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.

Volume 120, Issue 3, Pages (February 2001)

Group/causes of death Mortality (%) at 1 year Mortality (%) at 3 years

Differentiating Drug-Seeking Behavior From Poorly Controlled Pain

American Heart Association Scientific Sessions

NSAIDs: Risk of acute MI compared with remote use

Update on NSAID Use:.

Drug used within 3 months of index date Adjusted odds ratio* p

The American College of Cardiology Presented by Dr. Maurits T. Dirksen

American College of Cardiology Presented by Dr. Stephan Windecker

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

Volume 387, Issue 10033, Pages (May 2016)

Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

American Heart Association Presented by Dr. Julinda Mehilli

The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial Daniel H. Solomon, MD, MPH, M. Elaine.

Gastrointestinal Effects of NSAIDs and Coxibs

Trial Selection Process

Factors independently associated with odds of fractures

Cystatin C levels and risk of death from all causes

ARISE Trial Aggressive Reduction of Inflammation Stops Events

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Strategies in Pain Management

Characteristics of 21,484 Patients With MI Who Survived for >30 Days After Discharge, by Calendar Year - Part I Soko Setoguchi, et al. J Am Coll Cardiol.

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Nonsteroidal Anti-Inflammatory Drugs and Hepatic Toxicity: A Systematic Review of Randomized Controlled Trials in Arthritis Patients Alaa Rostom, Lawrence.

Results of Searches and Screening of Potentially Relevant Studies

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.

Orly Vardeny et al. JCHF 2016;4:

Presentation transcript:

Number of patients who received at least one prescription for a COX-2 inhibitor or NSAID after hospital discharge Drug Patients % of study cohort Rofecoxib 3 022 5.2 Celecoxib 2 489 4.3 Diclofenac 6 172 10.6 Ibuprofen 10 230 17.5 Other NSAIDs 7 449 12.7 Gislason G. American Heart Association Scientific Sessions 2005; Nov 13-16, 2005; Dallas, TX. COX-2 inhibitors/NSAIDs increase risk of death in patients with previous MI [Rheumawire > News; Nov 14, 2005

Hazard ratio for all-cause death in patients taking COX-2 inhibitors/NSAIDs vs those not taking such drugs Drug/dosage Hazard ratio for all-cause death Rofecoxib >25 mg/day 5.03 Rofecoxib lower doses 2.23 Celecoxib >200 mg/day 4.24 Celecoxib lower doses 1.70 Diclofenac >100 mg/day 3.76 Diclofenac lower doses 0.7 Ibuprofen >1200 mg/day 1.96 Ibuprofen lower doses 0.66 Other NSAIDs (any dose) 1.22 Gislason G. American Heart Association Scientific Sessions 2005; Nov 13-16, 2005; Dallas, TX. COX-2 inhibitors/NSAIDs increase risk of death in patients with previous MI [Rheumawire > News; Nov 14, 2005